Skip to search formSkip to main contentSkip to account menu

ramosetron hydrochloride

Known as: (R)-5-((1-Methyl-3-indolyl)carbonyl)-4,5,6,7-tetrahydro-1H-benzimidazole Hydrochloride, Methanone, (1-methyl-1H-indol-3-yl)(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)-, monohydrochloride, (R)- 
The hydrochloride salt of ramosetron, a selective serotonin (5-HT) receptor antagonist with potential antiemetic activity. Upon administration… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

Nasea
ramosetron

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Effect of total intravenous anaesthesia and prophylactic ramosetron on postoperative nausea and vomiting after thyroidectomy: A prospective, randomized controlled study
Objective To investigate the effect of combined prophylactic ramosetron and total intravenous anaesthesia (TIVA) on postoperative… 
2008
2008
Effect of Oral Ramosetron for Postoperative Nausea and Vomiting in Surgical Patients using Patient Controlled Analgesia
This study was designed to evaluate ramosetron oral disintegrating tablet (ODT), a 5-HT3 receptor antagonist, for prophylaxis and… 
2007
2007
Determination of Related Substances in Ramosetron Hydrochloride by HPLC
OBJECTIVE To develop a HPLC method for the determination of related substances and S-(+) enantiomer in ramosetron hydrochloride… 
2005
2005
Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
OBJECTIVE To evaluate the clinical efficacy of ramosetron hydrochloride in the combination with dexamethasone for the prevention… 
Review
2003
Review
2003
[Evaluation of QOL with orally disintegrating antiemetic tablets in outpatient chemotherapy].
An investigation into the effect of orally disintegrating antiemetic tablets (ramosetron OD 0.1 mg) on 16 outpatients undergoing… 
2002
2002
Contribution of P‐glycoprotein to efflux of ramosetron, a 5‐HT3 receptor antagonist, across the blood‐brain barrier
In‐situ rat and mouse brain perfusion data indicated that the brain distribution of ramosetron (R‐ramosetron), a 5… 
2001
2001
[Analysis of 5-HT3 receptor antagonist, ramosetron hydrochloride, based on receptor occupancy considering its active metabolite].
Severe nausea and vomiting induced by antineoplastics diminish the patient's quality of life and the ability to tolerate further… 
2001
2001
Ramosetron for the management of chemotherapy-induced gastrointestinal events in patients with hematological malignancies.
The objective of this study was to evaluate the efficacy and safety of ramosetron hydrochloride for the management of nausea and… 
2000
2000
Mucoadhesive suppositories of ramosetron hydrochloride utilizing Carbopol.
Review
1997
Review
1997
[A new antiemetic ramosetron hydrochloride].
Ramosetron hydrochloride as a 5-HT3 receptor antagonist-type antiemetic, which was developed in Japan. It has an indole ring… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)